⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668900 | 0.77 | — | — | |
| SCHEMBL670186 | 0.73 | KDM4E (0.31) | — | |
| SCHEMBL29564692 | 0.69 | — | — | |
| SCHEMBL15903863 | 0.67 | — | — | |
| SCHEMBL15903546 | 0.67 | — | — | |
| SCHEMBL15903796 | 0.66 | — | — | |
| SCHEMBL19972849 | 0.63 | KMT2A (0.34) | — | |
| SCHEMBL9938266 | 0.62 | KDM4E (0.30) | — | |
| SCHEMBL14941252 | 0.62 | — | — | |
| SCHEMBL3192528 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107753-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | NEUPHARMA, INC (US) | 2024-05-23 | — | — | WO | claimed |
| EP-2852285-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2015-04-01 | — | — | EP | claimed |
| WO-2013165924-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-11-07 | — | — | WO | claimed |
| WO-2024107753-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | NEUPHARMA, INC (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-2852285-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013165924-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-11-07 | — | — | WO | disclosed |